<?xml version="1.0" encoding="UTF-8"?>
<p>Combination treatment dosed QID for seven days has also been shown to improve clinical scores for scleral inflammation, ocular neovascularization, eyelid inflammation, friability of vasculature, inflammatory discharge, and epiphora as compared to treatment with 0.5% cidofovir, tobramycin/dexamethasone ophthalmic suspension, and balanced salt solution in rabbit models.
 <xref rid="CIT0052" ref-type="bibr">52</xref> Moreover, PVI/dexamethasone combination has proven effective in reducing viral titers and delaying viral shedding.
 <xref rid="CIT0052" ref-type="bibr">52</xref>
</p>
